TWST at a glance
Twist Bioscience Corp (TWST, SEC CIK 1581280) filed its latest 10-K annual report on November 17, 2025, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 19, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), Twist Bioscience Corp (TWST) reported revenue of $376.6 million (up 20.3% from FY2024) and a net loss of $77.7 million. Diluted EPS was -$1.30.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Twist Bioscience Corp (TWST) shares worth $3.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Finn Patrick John on October 2, 2026 of 25,714 shares at $188.88 per share.
- In the last 90 days, TWST insiders reported 0 open-market purchases ($0) and 69 open-market sales ($118.9M) on Form 4, a net sale of $118.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $376.6M
- +20.3% vs prior year
- Insiders · 90 days
- 0 buys · 69 sells
- Net −$118.9M
- 13F holders
- 33 funds
- $3.9B · +2 vs prior quarter
- Latest 8-K
- Aug 19, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2025
Business Overview
- Core business: Synthetic DNA production and related biotechnological research and manufacturing
- Strategic real estate expansion: Lease amendment adds 33,000 sq. ft. for R&D, manufacturing, and administration in South San Francisco
- Lease extended to June 30, 2036 with $119.2M total rent obligations including 3% annual rent escalations
- $24.4M tenant improvement allowance from landlord to support facility upgrades
- Option to expand by another 33,000 sq. ft. by December 31, 2026 on fourth floor
Risk Factors
- Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
- Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption
- Operational vulnerability: reliance on single-source supplier for critical DNA synthesis component risking production delays
- Competitive risk: rivalry with Thermo Fisher Scientific, Illumina, and others who may develop silicon chip synthetic DNA technologies threatening market position
- Financial risk: accumulated deficit $1,319.6M and net losses $204.6M-$208.7M in prior years raising sustainability concerns
Management Discussion & Analysis
- Revenue $376.6M, up 20% YoY from $313.0M, driven by NGS tools +$39.0M and synthetic genes +$20.9M
- Gross margin 50.7% vs 42.6%, up 8.1% due to revenue growth and flat fixed manufacturing costs
- Best segment: NGS tools $208.1M (55% of revenue), worst: DNA libraries $11.2M (3% of revenue)
- Net cash used in operating activities $47.6M vs $64.1M; capital expenditures $28.0M; financing cash inflow $28.5M including $15.0M from royalty sale
- Management expects current cash, investments and operations to fund >12 months but may raise financing if needed; significant lease expansion signed through 2036
AI summary of the TWST 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $118.4M, up 23% YoY from $96.1M, led by DNA synthesis and protein solutions growth of 39%
- Gross margin 52.8% vs 53.4% YoY, primarily due to customer mix
- NGS applications largest product line at $61.8M, 52% of quarterly revenue; DNA synthesis and protein solutions $56.6M
- Cash and short-term investments $166.8M; nine-month operating cash use $41.3M vs $35.8M
- Outlook: SG&A expected to moderate in Q4 fiscal 2026; liquidity sufficient for more than 12 months, with $200.0M ATM capacity unused
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Insider selling risk: CEO trading plan covering approximately 624,134 shares
- Insider selling risk: COO trading plan covering up to 78,355 shares
- Insider selling risk: Director trading plan covering up to 18,417 shares
- Financing risk: June 18, 2026 sales agreement with TD Securities (USA) LLC
AI summary of the TWST 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Filing contains only execution signatures dated August 18, 2026
- No substantive Regulation FD disclosure or investor-relevant information provided in the submitted text
Item 8.01: Other Events
- Twist filing prospectus supplement registering Invenra’s resale of shares issuable under February 11, 2026 Stock Purchase Agreement
- Potential increase in tradable shares and resale-related dilution overhang for existing shareholders
Item 1.01: Entry into a Material Definitive Agreement
- Equity offering expanded to 3,593,750 shares at $96.00 per share, including fully exercised 468,750-share option
- Approximately $327.1 million net proceeds expected after underwriting discounts and offering expenses
Item 7.01: Regulation FD Disclosure
- Proposed equity offering increased from $250.0 million to an upsized $300.0 million
- Pricing indicates stronger-than-anticipated demand, but creates potential shareholder dilution
Item EX-99.1: Item EX-99.1
- Proposed $250.0M underwritten common-stock offering, creating dilution risk for existing shareholders
- Additional underwriter option for up to $37.5M, potentially increasing total issuance
AI summaries of TWST 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TWST
Don't miss the next TWST filing
- Alerts as it files. A push when TWST files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TWST, by share count.
- Ask anything. An AI agent that reads every TWST filing and answers with sources.
TWST alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Finn Patrick John | Sell | Oct 2, 2026 | 25,714 | $188.88 |
| Cho Dennis | Sell | Oct 2, 2026 | 9,514 | $188.88 |
| Laponis Adam | Sell | Oct 2, 2026 | 8,057 | $188.88 |
| WERNER ROBERT F. | Sell | Oct 2, 2026 | 1,482 | $188.88 |
| Green Paula | Sell | Oct 2, 2026 | 10,088 | $188.88 |
| Leproust Emily M. | Sell | Oct 2, 2026 | 45,736 | $188.88 |
| Leproust Emily M. | Sell | Oct 1, 2026 | 655 | $200.00 |
| Leproust Emily M. | Sell | Sep 24, 2026 | 143 | $179.93 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $313.0M | $376.6M |
| Operating Income | -$217.2M | -$220.8M | -$136.3M |
| Net Income | -$204.6M | -$208.7M | -$77.7M |
| Op. Margin | - | -70.6% | -36.2% |
| Net Margin | - | -66.7% | -20.6% |
| Balance Sheet | |||
| Total Assets | - | $614.3M | $641.9M |
| Equity | - | $472.7M | $473.0M |
| ROE | - | -44.2% | -16.4% |
| Per Share | |||
| EPS | $-3.60 | $-3.60 | $-1.30 |
| Cash Flow | |||
| Operating CF | - | -$64.1M | -$47.6M |
| CapEx | $27.8M | $5.1M | $28.0M |
Source: XBRL data in Twist Bioscience Corp (TWST)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TWST share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $3.89B |
| Q1 2026 | 31 | $1.52B |
| Q4 2025 | 24 | $992.2M |
| Q3 2025 | 26 | $958.5M |
| Q2 2025 | 28 | $1.23B |
| Q1 2025 | 27 | $1.04B |
| Q4 2024 | 23 | $1.11B |
| Q3 2024 | 19 | $808.4M |
- T. Rowe Price Group+3.56M (+5070%)
- FMR LLC (Fidelity)+2.81M (+149%)
- D.E. Shaw & Co+1.14M (+2442%)
- Morgan Stanley+643.0K (+118%)
- Bank of America Corp+338.4K (+58%)
- ARK Investment Management−1.79M (-28%)
- State Street Corp−438.1K (-12%)
- Citigroup−382.7K (-83%)
- Citadel Advisors LLC−358.4K (-29%)
- Goldman Sachs Group−297.1K (-17%)
- Bridgewater Associates LP+18.6K
- Allstate+2.6K
- M&T Bank+2.4K
- Marex Group plc−9.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 211 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TWST filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TWST SEC filings: frequently asked questions
Are TWST insiders buying or selling?
In the last 90 days, Twist Bioscience Corp (TWST) officers, directors and 10% owners reported no open-market purchases and 69 open-market sales worth $118.9 million by 8 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TWST stock?
As of June 30, 2026, the largest Twist Bioscience Corp (TWST) holders among the 13F filers tracked by SignalX were BlackRock ($600.2 million), FMR LLC (Fidelity) ($483.8 million), ARK Investment Management ($468.1 million), T. Rowe Price Group ($373.9 million), State Street Corp ($332.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TWST's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), Twist Bioscience Corp (TWST) reported revenue of $376.6 million (up 20.3% from FY2024) and a net loss of $77.7 million. Diluted EPS was -$1.30. The figures come from the XBRL data in the 10-K.
What are the main risks in TWST's latest 10-K?
In the 10-K filed November 17, 2025, Twist Bioscience Corp (TWST) flagged: Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection. Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption. (AI summary of the Risk Factors section.)
What did TWST report in its latest 8-K?
Twist Bioscience Corp (TWST) filed an 8-K on August 19, 2026 reporting Item 7.01 (Regulation FD Disclosure). Filing contains only execution signatures dated August 18, 2026.
What are the latest TWST SEC filings?
Twist Bioscience Corp (TWST) filed its latest 10-K annual report on November 17, 2025, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 19, 2026 and a Form 4 insider filing on October 5, 2026.
What is TWST's SEC CIK number?
Twist Bioscience Corp (TWST)'s SEC Central Index Key (CIK) is 1581280. EDGAR lists every TWST filing under that number.
Ask anything about TWST
The research agent reads TWST's filings, financials, insider trades and 13F holders, then answers with sources.